Health Economics›Mantle cell lymphoma›First-line therapy non-randomized or retrospective data

First-line therapy non-randomized or retrospective data

Mantle cell lymphoma · 19 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Lenalidomide and Rituximab (R2) Variant #10	—	R 86 746	35d	—	~8.5 mo	—	—	1
Cladribine monotherapy Variant #01	—	R 59 905	5d	—	—	—	—	—
maxi-R-CHOP/R-HiDAC Variant #01	—	R 57 159	21d	—	—	—	—	—
R-DHAOx Variant #02	—	R 51 858	21d	—	—	—	—	—
RiPAD+C Variant #01	—	R 41 791	35d	—	—	—	—	—
BR/RC Variant #01	—	R 37 799	28d	—	—	—	—	—
Cladribine and Rituximab Variant #01	—	R 33 968	21d	—	—	—	—	—
R-BAC Variant #02	—	R 29 564	28d	—	—	—	—	—
Chlorambucil and Rituximab (RClb) Variant #03	—	R 28 365	28d	~23.1 mo	—	~26	~R 737 482 PFS proxy · indirect	3
R-HiDAC Variant #01	—	R 23 513	11d	—	—	—	—	—
R-DHAP Variant #06	—	R 17 673	21d	—	~31.1 mo	—	—	2
R-DHAC Variant #01	—	R 16 098	21d	—	—	—	—	—
VcR-CVAD Variant #01	—	R 15 746	21d	—	—	—	—	—
VR-CHOP Variant #01	—	R 14 802	21d	—	—	—	—	—
R-VAD+C Variant #01	—	R 14 152	35d	—	—	—	—	—
R-CODOX-M/R-IVAC N/A - intrathecal component	—	R 12 115	—	—	—	—	—	1
Rituximab monotherapy N/A - secondary systemic drug	—	R 52	180d	~5.2 mo	—	~1	~R 52 PFS proxy · indirect	3
R-M-CHOP Partial	—	—	—	—	—	—	—	—
Watchful waiting Partial	—	—	—	~12.9 mo	—	—	—	—

19 of 19 regimens shown